Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVAPERL: Bevacizumab +/- Pemetrexed Maintenance in NSCLC
NCT00961415Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2009
- Primary completion
- May 2011
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (3 arms), sponsored by Roche. Primary endpoint: Progression Free Survival During Maintenance Treatment Phase up to 21 months. Started Aug 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT00961415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00961415.